Serveur d'exploration sur les dispositifs haptiques

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Outcome of phacoemulsification in patients with uveitis

Identifieur interne : 005697 ( Main/Exploration ); précédent : 005696; suivant : 005698

Outcome of phacoemulsification in patients with uveitis

Auteurs : M A Elgohary [Royaume-Uni, Égypte] ; P J Mccluskey [Australie] ; H M A. Towler [Royaume-Uni] ; N. Okhravi [Royaume-Uni] ; R P Singh [Australie] ; R. Obikpo [Royaume-Uni] ; S S Lightman [Royaume-Uni]

Source :

RBID : ISTEX:81BEA7A9CAC0F7C8AA51E2570BAC02B0924139B9

Descripteurs français

English descriptors

Abstract

Aims: To examine the visual outcome and identify risk factors for postoperative uveitis, macular oedema and neodymium-doped yttrium aluminium garnet (Nd:YAG) capsulotomy after phacoemulsification and intraocular lens (IOL) implantation in patients with uveitis. Method: This is a retrospective review of the medical records of 101 eyes of 101 patients. One eye was randomly selected for inclusion in patients who had bilateral surgery. Patients with juvenile arthritis, keratouveitis and lymphoma-associated uveitis were excluded. Results: At the first postoperative and final visits, visual acuity was significantly better (p<0.001), and 64.4% and 71.3% of patients, respectively, had achieved ⩾2 Snellen’s lines of visual improvement. The cumulative probability of doubling of the visual angle was 52% over 6 years of follow-up, and this occurred at a higher rate in the presence of preoperative retinal or optic nerve lesions (HR (95% CI) 4.49 (1.41 to 14.29)). Within 3 months after operation, uveitis was more likely to develop in female patients (OR (95% CI) 6.21 (1.41 to 27.43)) and in the presence of significant intraoperative posterior synechiae (OR (95% CI) 8.43 (1.09 to 65.41)); macular oedema was more likely to develop in patients who developed postoperative uveitis (OR (95% CI) 7.45 (1.63 to 34.16)). Nd:YAG capsulotomy occurred at a higher rate in patients aged ⩽55 years (HR (95% CI) 2.28 (1.06, 4.93)) and in those with hydrogel IOLs (HR (95% CI) 3.71 (1.04 to 13.20)), and occurred at a lower rate in patients who had prophylactic systemic corticosteroids (HR (95% CI) 0.25 (0.11 to 0.59)), with plate-haptic silicone IOLs (HR (95% CI) 0.23 (0.08 to 0.64)) and three-piece silicone IOLs (HR (95% CI) 0.19 (0.05 to 0.74)) in comparison to those with polymethylmethacrylate IOLs. Conclusion: Most patients with uveitis achieve improved visual acuity after phacoemulsification, but an increasing rate of visual loss is observed in those with pre-existent macular or optic nerve lesions. Identifying patients who are at risk of postoperative complications should help in patient counselling and to pre-empt these complications by using preoperative prophylactic corticosteroids, careful IOL selection and postoperative intensive corticosteroids.

Url:
DOI: 10.1136/bjo.2006.109660


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI wicri:istexFullTextTei="biblStruct">
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Outcome of phacoemulsification in patients with uveitis</title>
<author>
<name sortKey="Elgohary, M A" sort="Elgohary, M A" uniqKey="Elgohary M" first="M A" last="Elgohary">M A Elgohary</name>
</author>
<author>
<name sortKey="Mccluskey, P J" sort="Mccluskey, P J" uniqKey="Mccluskey P" first="P J" last="Mccluskey">P J Mccluskey</name>
</author>
<author>
<name sortKey="Towler, H M A" sort="Towler, H M A" uniqKey="Towler H" first="H M A" last="Towler">H M A. Towler</name>
</author>
<author>
<name sortKey="Okhravi, N" sort="Okhravi, N" uniqKey="Okhravi N" first="N" last="Okhravi">N. Okhravi</name>
</author>
<author>
<name sortKey="Singh, R P" sort="Singh, R P" uniqKey="Singh R" first="R P" last="Singh">R P Singh</name>
</author>
<author>
<name sortKey="Obikpo, R" sort="Obikpo, R" uniqKey="Obikpo R" first="R" last="Obikpo">R. Obikpo</name>
</author>
<author>
<name sortKey="Lightman, S S" sort="Lightman, S S" uniqKey="Lightman S" first="S S" last="Lightman">S S Lightman</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:81BEA7A9CAC0F7C8AA51E2570BAC02B0924139B9</idno>
<date when="2007" year="2007">2007</date>
<idno type="doi">10.1136/bjo.2006.109660</idno>
<idno type="url">https://api.istex.fr/document/81BEA7A9CAC0F7C8AA51E2570BAC02B0924139B9/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">002027</idno>
<idno type="wicri:Area/Istex/Curation">002027</idno>
<idno type="wicri:Area/Istex/Checkpoint">001861</idno>
<idno type="wicri:doubleKey">0007-1161:2007:Elgohary M:outcome:of:phacoemulsification</idno>
<idno type="wicri:Area/Main/Merge">005884</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:07-0303695</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000B40</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000955</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000801</idno>
<idno type="wicri:doubleKey">0007-1161:2007:Elgohary M:outcome:of:phacoemulsification</idno>
<idno type="wicri:Area/Main/Merge">005B73</idno>
<idno type="wicri:source">PMC</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1955648</idno>
<idno type="RBID">PMC:1955648</idno>
<idno type="wicri:Area/Pmc/Corpus">000A52</idno>
<idno type="wicri:Area/Pmc/Curation">000A52</idno>
<idno type="wicri:Area/Pmc/Checkpoint">002439</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="wicri:Area/PubMed/Corpus">001712</idno>
<idno type="wicri:Area/PubMed/Curation">001712</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001392</idno>
<idno type="wicri:Area/Ncbi/Merge">000A55</idno>
<idno type="wicri:Area/Ncbi/Curation">000A55</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000A55</idno>
<idno type="wicri:doubleKey">0007-1161:2007:Elgohary M:outcome:of:phacoemulsification</idno>
<idno type="wicri:Area/Main/Merge">005527</idno>
<idno type="wicri:Area/Main/Curation">005697</idno>
<idno type="wicri:Area/Main/Exploration">005697</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title level="a" type="main" xml:lang="en">Outcome of phacoemulsification in patients with uveitis</title>
<author>
<name sortKey="Elgohary, M A" sort="Elgohary, M A" uniqKey="Elgohary M" first="M A" last="Elgohary">M A Elgohary</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Moorfields Eye Hospital, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
<affiliation wicri:level="1">
<country xml:lang="fr">Égypte</country>
<wicri:regionArea>Tanta University Ophthalmology Hospital, Tanta</wicri:regionArea>
<wicri:noRegion>Tanta</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Mccluskey, P J" sort="Mccluskey, P J" uniqKey="Mccluskey P" first="P J" last="Mccluskey">P J Mccluskey</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Royal Prince Alfred Hospital, Sydney, New South Wales</wicri:regionArea>
<wicri:noRegion>New South Wales</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Towler, H M A" sort="Towler, H M A" uniqKey="Towler H" first="H M A" last="Towler">H M A. Towler</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Whipps Cross University Hospital, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Okhravi, N" sort="Okhravi, N" uniqKey="Okhravi N" first="N" last="Okhravi">N. Okhravi</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Moorfields Eye Hospital, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Singh, R P" sort="Singh, R P" uniqKey="Singh R" first="R P" last="Singh">R P Singh</name>
<affiliation wicri:level="1">
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Royal Prince Alfred Hospital, Sydney, New South Wales</wicri:regionArea>
<wicri:noRegion>New South Wales</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Obikpo, R" sort="Obikpo, R" uniqKey="Obikpo R" first="R" last="Obikpo">R. Obikpo</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Whipps Cross University Hospital, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author>
<name sortKey="Lightman, S S" sort="Lightman, S S" uniqKey="Lightman S" first="S S" last="Lightman">S S Lightman</name>
<affiliation wicri:level="3">
<country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Moorfields Eye Hospital, London</wicri:regionArea>
<placeName>
<settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series>
<title level="j">British Journal of Ophthalmology</title>
<title level="j" type="abbrev">Br J Ophthalmol</title>
<idno type="ISSN">0007-1161</idno>
<idno type="eISSN">1468-2079</idno>
<imprint>
<publisher>BMJ Publishing Group Ltd.</publisher>
<pubPlace>BMA House, Tavistock Square, London, WC1H 9JR</pubPlace>
<date type="published" when="2007-07">2007-07</date>
<biblScope unit="volume">91</biblScope>
<biblScope unit="issue">7</biblScope>
<biblScope unit="page" from="916">916</biblScope>
</imprint>
<idno type="ISSN">0007-1161</idno>
</series>
<idno type="istex">81BEA7A9CAC0F7C8AA51E2570BAC02B0924139B9</idno>
<idno type="DOI">10.1136/bjo.2006.109660</idno>
<idno type="href">bjophthalmol-91-916.pdf</idno>
<idno type="PMID">17229800</idno>
<idno type="local">0910916</idno>
</biblStruct>
</sourceDesc>
<seriesStmt>
<idno type="ISSN">0007-1161</idno>
</seriesStmt>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Cataract (complications)</term>
<term>Epiretinal Membrane (etiology)</term>
<term>Evolution</term>
<term>Female</term>
<term>Human</term>
<term>Humans</term>
<term>Lens Capsule, Crystalline (surgery)</term>
<term>Macular Edema (etiology)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Ocular Hypertension (etiology)</term>
<term>Ophthalmology</term>
<term>Phacoemulsification</term>
<term>Phacoemulsification (adverse effects)</term>
<term>Prognosis</term>
<term>Recurrence</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Surgery</term>
<term>Survival Analysis</term>
<term>Treatment</term>
<term>Treatment Outcome</term>
<term>Uveitis</term>
<term>Uveitis (complications)</term>
<term>Visual Acuity</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en">
<term>Phacoemulsification</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Cataract</term>
<term>Uveitis</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en">
<term>Epiretinal Membrane</term>
<term>Macular Edema</term>
<term>Ocular Hypertension</term>
</keywords>
<keywords scheme="MESH" qualifier="surgery" xml:lang="en">
<term>Lens Capsule, Crystalline</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Adolescent</term>
<term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Prognosis</term>
<term>Recurrence</term>
<term>Retrospective Studies</term>
<term>Risk Factors</term>
<term>Survival Analysis</term>
<term>Treatment Outcome</term>
<term>Visual Acuity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr">
<term>Chirurgie</term>
<term>Evolution</term>
<term>Homme</term>
<term>Ophtalmologie</term>
<term>Phacoémulsification</term>
<term>Pronostic</term>
<term>Traitement</term>
<term>Uvéite</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr">
<term>Chirurgie</term>
<term>Homme</term>
</keywords>
</textClass>
<langUsage>
<language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Aims: To examine the visual outcome and identify risk factors for postoperative uveitis, macular oedema and neodymium-doped yttrium aluminium garnet (Nd:YAG) capsulotomy after phacoemulsification and intraocular lens (IOL) implantation in patients with uveitis. Method: This is a retrospective review of the medical records of 101 eyes of 101 patients. One eye was randomly selected for inclusion in patients who had bilateral surgery. Patients with juvenile arthritis, keratouveitis and lymphoma-associated uveitis were excluded. Results: At the first postoperative and final visits, visual acuity was significantly better (p<0.001), and 64.4% and 71.3% of patients, respectively, had achieved ⩾2 Snellen’s lines of visual improvement. The cumulative probability of doubling of the visual angle was 52% over 6 years of follow-up, and this occurred at a higher rate in the presence of preoperative retinal or optic nerve lesions (HR (95% CI) 4.49 (1.41 to 14.29)). Within 3 months after operation, uveitis was more likely to develop in female patients (OR (95% CI) 6.21 (1.41 to 27.43)) and in the presence of significant intraoperative posterior synechiae (OR (95% CI) 8.43 (1.09 to 65.41)); macular oedema was more likely to develop in patients who developed postoperative uveitis (OR (95% CI) 7.45 (1.63 to 34.16)). Nd:YAG capsulotomy occurred at a higher rate in patients aged ⩽55 years (HR (95% CI) 2.28 (1.06, 4.93)) and in those with hydrogel IOLs (HR (95% CI) 3.71 (1.04 to 13.20)), and occurred at a lower rate in patients who had prophylactic systemic corticosteroids (HR (95% CI) 0.25 (0.11 to 0.59)), with plate-haptic silicone IOLs (HR (95% CI) 0.23 (0.08 to 0.64)) and three-piece silicone IOLs (HR (95% CI) 0.19 (0.05 to 0.74)) in comparison to those with polymethylmethacrylate IOLs. Conclusion: Most patients with uveitis achieve improved visual acuity after phacoemulsification, but an increasing rate of visual loss is observed in those with pre-existent macular or optic nerve lesions. Identifying patients who are at risk of postoperative complications should help in patient counselling and to pre-empt these complications by using preoperative prophylactic corticosteroids, careful IOL selection and postoperative intensive corticosteroids.</div>
</front>
</TEI>
<affiliations>
<list>
<country>
<li>Australie</li>
<li>Royaume-Uni</li>
<li>Égypte</li>
</country>
<region>
<li>Angleterre</li>
<li>Grand Londres</li>
</region>
<settlement>
<li>Londres</li>
</settlement>
</list>
<tree>
<country name="Royaume-Uni">
<region name="Angleterre">
<name sortKey="Elgohary, M A" sort="Elgohary, M A" uniqKey="Elgohary M" first="M A" last="Elgohary">M A Elgohary</name>
</region>
<name sortKey="Lightman, S S" sort="Lightman, S S" uniqKey="Lightman S" first="S S" last="Lightman">S S Lightman</name>
<name sortKey="Obikpo, R" sort="Obikpo, R" uniqKey="Obikpo R" first="R" last="Obikpo">R. Obikpo</name>
<name sortKey="Okhravi, N" sort="Okhravi, N" uniqKey="Okhravi N" first="N" last="Okhravi">N. Okhravi</name>
<name sortKey="Towler, H M A" sort="Towler, H M A" uniqKey="Towler H" first="H M A" last="Towler">H M A. Towler</name>
</country>
<country name="Égypte">
<noRegion>
<name sortKey="Elgohary, M A" sort="Elgohary, M A" uniqKey="Elgohary M" first="M A" last="Elgohary">M A Elgohary</name>
</noRegion>
</country>
<country name="Australie">
<noRegion>
<name sortKey="Mccluskey, P J" sort="Mccluskey, P J" uniqKey="Mccluskey P" first="P J" last="Mccluskey">P J Mccluskey</name>
</noRegion>
<name sortKey="Singh, R P" sort="Singh, R P" uniqKey="Singh R" first="R P" last="Singh">R P Singh</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Ticri/CIDE/explor/HapticV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005697 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005697 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Ticri/CIDE
   |area=    HapticV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:81BEA7A9CAC0F7C8AA51E2570BAC02B0924139B9
   |texte=   Outcome of phacoemulsification in patients with uveitis
}}

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Mon Jun 13 01:09:46 2016. Site generation: Wed Mar 6 09:54:07 2024